EQT will pay €46.50 for Qiagen. Thermo Fisher's €43 failed in 2020.
EQT's €10.8bn Qiagen bid is 8.1% above the offer that lapsed at 47% acceptance in 2020. The bar is lower on paper, and the fund paying has not yet started.
Read more
Ares Capital's dividend has outrun its core earnings three quarters running.
Core EPS of $0.46 trails the $0.48 dividend for a third straight quarter. Income from controlled affiliates is carrying more of a smaller total.
Operating benches outhire deal teams as Insight Partners loses three
Seven operating hires beat six deal-team hires in a 25-move week. Insight Partners lost three senior people, and the head of private equity at a big state pension crossed to a GP.
OpenAI's $200 plan now buys less. Its new $500 plan buys speed.
The $200 ChatGPT Pro tier is back with a smaller allowance. The $500 tier's headline feature burns that allowance at eight times the normal rate.
